

# 'Tough Choices' Feared on HPV Vaccine Access

BY HEIDI SPLETE  
Senior Writer

WASHINGTON — The challenge of paying for vaccinations has become even greater now that the human papilloma virus vaccine is on the immunization schedule.

At a meeting of the National Vaccine Advisory Committee, representatives from several organizations reported that there isn't enough money to go around and that states will have to make tough choices about funding for the HPV vaccine, which is scheduled to become a standard immunization for 11- to 12-year-old girls.

The evidence used by the Advisory Committee on Immunization Practices to make vaccine recommendations includes economic factors as part of the public health perspective, said Dr. Lance Rodewald, director of the immunization services division at the Centers for Disease Control and Prevention.

However, the price of a vaccine is not allowed to be a consideration for resolutions made by the Vaccines for Children

**Uninsured individuals aged 9-18 will be covered by VFC, and coverage for uninsured females aged 9-26 may be available through a Merck aid program.**

(VFC) program. The key consideration in a VFC resolution simply is whether the vaccine is recommended for VFC-eligible children, he said.

Consequently, an ACIP recommendation raises the possibility for disparity, with VFC-

eligible children receiving a vaccine because it is paid for, and children with private insurance not receiving the same vaccine because it is not paid for.

Neither state-appropriated funds nor funds from Section 317 (a discretionary program within the Public Health Service Act that covers individuals whose insurance doesn't cover vaccines or who are not eligible for VFC funds) has kept up with VFC's need-based funding, Dr. Rodewald said.

What happens when the need outstrips the resources? "The programs are put in a tough spot," he said. "The states will need to prioritize vaccinations, and we are looking to other groups to help resolve the financing dilemma."

Dr. Poki Stewart Namkung, president of the National Association of County & City Health Officials, shared responses to a survey that solicited their members' concerns about implementing HPV vaccines. Key issues raised by the local health departments included how to vaccinate girls and young women who fall outside the bounds of public assistance given the limitations of the VFC program and Section 317.

States will receive VFC funding, but do not know what other funds to expect, said Claire Hannan, executive director of

the Association of Immunization Managers (AIM). Ms. Hannan said AIM members are involved in every aspect of vaccination, including distribution, purchasing, and provider and consumer education.

Uninsured individuals aged 9-18 years will be covered by VFC, and limited coverage for uninsured females aged 9-26 years may be available through Merck & Co.'s vaccine assistance program. Insured individuals are covered in theory, but AIM members are concerned that as

new, expensive vaccines are added to the vaccine schedule, more insurance plans will not cover all the vaccines, Ms. Hannan said.

"Programs are making decisions about how to use limited funds, and they are making different decisions," she said. The result is a patchwork of vaccination coverage. Possible solutions to the problem of patchwork coverage could include enlisting the help of ob.gyns. and dermatologists, since they treat children and adoles-

cents and could enroll their eligible younger patients in the VFC program, Ms. Hannan said.

No one knows how the financing for HPV vaccines will play out until the vaccine actually is in use, but vaccine financing is dynamic because both the payments and the individual insurance plans change annually, said Dr. Gregory Wallace of the CDC's National Immunization Program. "Difficult decisions have to be made with competing priorities every year." ■

## Our Name Has Gone Pro.

Albuterol Sulfate HFA has a new name:

**ProAir™ HFA**  
(albuterol sulfate) Inhalation Aerosol

**Prescribe ProAir HFA** to ensure patients continue to:

- Receive the #1 dispensed albuterol sulfate HFA\*
- Depend on the same medication they've been using

ProAir™ HFA is indicated in adults and children 12 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Inhaled albuterol sulfate can produce paradoxical bronchospasm that may be life threatening. It should be recognized that paradoxical bronchospasm, when associated with inhaled formulations, frequently occurs with the first use of a new canister. ProAir HFA, as with all sympathomimetic amines, should be used with caution in patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), convulsive disorders, hyperthyroidism, and diabetes. Do not exceed the recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. Potential drug interactions can occur with beta blockers, diuretics, digoxin, or monoamine oxidase inhibitor and tricyclic antidepressants.

Adverse events, which occurred at an incidence rate of at least 3% with ProAir HFA, include headache, tachycardia, pain, dizziness, pharyngitis and rhinitis.

Please see brief summary of prescribing information on next page.  
\*IMS Health National Prescription Audit. April 2006.



© 2006 IVAX Laboratories, Inc.  
ProAir™ HFA is a trademark of IVAX Laboratories, Inc.

PRT# 5449-0406